OPEN END-TURBO-OPTIONSSCHEIN - NOVO NORDISK ADR B | Real-time BOERSE MUENCHEN 01:05:10 29/06/2024 am IST | ||
| 17.18 EUR | -1.43% |
|
| Current month | +11.34% | ||
| 1 month | +11.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 17.18 | -1.43% |
| 27/24/27 | 17.43 | +0.29% |
| 26/24/26 | 17.38 | -2.85% |
| 25/24/25 | 17.89 | +5.36% |
| 24/24/24 | 16.98 | -0.06% |
Real-time BOERSE MUENCHEN
Last update June 29, 2024 at 01:05 am IST
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | HSBC |
| WKN | TT94EE |
| ISIN | DE000TT94EE2 |
| Date issued | 12/11/2021 |
| Strike | 51.31 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 2.29 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.12 € |
|---|---|
| Lowest since issue | 0.4 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- Certificat
